{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:08:39Z","timestamp":1791328119398,"version":"4.3.1"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1097\/mph.0b013e318266bf34","type":"journal-article","created":{"date-parts":[[2012,12,18]],"date-time":"2012-12-18T09:40:34Z","timestamp":1355823634000},"page":"e1-e3","source":"Crossref","is-referenced-by-count":25,"title":["Persistent Complete Response After Single-agent Sunitinib Treatment in a Case of TFE Translocation Positive Relapsed Metastatic Pediatric Renal Cell Carcinoma"],"prefix":"10.1097","volume":"35","author":[{"given":"Tanzina","family":"Chowdhury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Prichard-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil J.","family":"Sebire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly","family":"Bier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Cherian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen O.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"O\u2019Meara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-16-20210227","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s10024-005-1156-7","article-title":"Pediatric renal tumors: practical updates for the pathologist.","volume":"8","author":"Perlman","year":"2005","journal-title":"Pediatr Dev Pathol"},{"key":"R2-16-20210227","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1080\/00313020310001619901","article-title":"Distinctive neoplasms characterised by specific chromosomal translocations comprise a significant proportion of paediatric renal cell carcinomas.","volume":"35","author":"Argani","year":"2003","journal-title":"Pathology"},{"key":"R3-16-20210227","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/cncr.23331","article-title":"Translocation renal cell carcinoma: lack of negative impact due to lymph node spread.","volume":"112","author":"Geller","year":"2008","journal-title":"Cancer"},{"key":"R4-16-20210227","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00125480-200309000-00001","article-title":"Recent advances in pediatric renal neoplasia.","volume":"10","author":"Argani","year":"2003","journal-title":"Adv Anat Pathol"},{"key":"R5-16-20210227","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/00000478-200306000-00005","article-title":"Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay.","volume":"27","author":"Argani","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"R6-16-20210227","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1093\/hmg\/ddg178","article-title":"Upregulation of the transcription factor TFEB in t(6;11)(p21;q13)-positive renal cell carcinomas due to promoter substitution.","volume":"12","author":"Kuiper","year":"2003","journal-title":"Hum Mol Genet"},{"key":"R7-16-20210227","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3322\/canjclin.57.2.112","article-title":"Recent progress in the management of advanced renal cell carcinoma.","volume":"57","author":"Garcia","year":"2007","journal-title":"CA Cancer J Clin"},{"key":"R8-16-20210227","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/annonc\/mdq029","article-title":"Targeted agents in metastatic Xp11 translocationTFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.","volume":"21","author":"Malouf","year":"2010","journal-title":"Ann Oncol"},{"key":"R9-16-20210227","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.urolonc.2009.10.007","article-title":"An adult Xp11 .2 translocation renal carcinoma showing response to treatment with sunitinib.","volume":"29","author":"Pwint","year":"2011","journal-title":"Urol Oncol"},{"key":"R10-16-20210227","doi-asserted-by":"crossref","first-page":"E93","DOI":"10.3816\/CGC.2009.n.031","article-title":"A case of adult metastatic Xp11 translocation renal cell carcinoma treated successfully with sunitinib.","volume":"7","author":"Choueiri","year":"2009","journal-title":"Clin Genitourin Cancer"},{"key":"R11-16-20210227","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10147-010-0154-6","article-title":"A case study of metastatic Xp11.2 translocation renal cell carcinoma effectively treated with sunitinib.","volume":"16","author":"Numakura","year":"2011","journal-title":"Int J Clin Oncol"},{"key":"R12-16-20210227","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1200\/JCO.2005.01.186","article-title":"Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma.","volume":"23","author":"Rini","year":"2005","journal-title":"J Clin Oncol"},{"key":"R13-16-20210227","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1158\/0008-5472.CAN-08-4323","article-title":"Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells.","volume":"69","author":"Xin","year":"2009","journal-title":"Cancer Res"},{"key":"R14-16-20210227","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1158\/0008-5472.CAN-06-2855","article-title":"TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition.","volume":"67","author":"Tsuda","year":"2007","journal-title":"Cancer Res"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0b013e318266bf34","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T04:13:09Z","timestamp":1620965589000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201301000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0b013e318266bf34","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}